Journal
CANCER CELL
Volume 40, Issue 2, Pages 131-133Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.01.013
Keywords
-
Categories
Ask authors/readers for more resources
Two recent reports highlight the successful application of novel targeted therapies to improve clinical outcomes of DLBCL. These findings encourage further exploration of mechanism-based treatments to make DLBCL curable in the era of precision medicine.
Two recent reports in the New England Journal of Medicine highlight the successful application of novel tar-geted therapies to improve the clinical outcomes of diffuse large B-cell lymphoma (DLBCL). These findings encourage us to pursue further mechanism-based therapeutic uses to make DLBCL curable in the era of pre-cision medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
